Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients

BackgroundA limitation of positive selection strategies to enrich for circulating tumor cells (CTCs) is that there might be CTCs with insufficient expression of the surface target marker which may be missed by the procedure. We optimized a method for enrichment, subsequent detection and characterization of CTCs based on depletion of the leukocyte fraction.MethodsThe 2-step protocol was developed for processing 20 mL blood and based on red blood cell lysis followed by leukocyte depletion. The remaining material was stained with the epithelial markers EpCAM and cytokeratin (CK) 7/8 or for the melanoma marker HMW-MAA/MCSP. CTCs were detected by flow cytometry. CTCs enriched from blood of patients with carcinoma were defined as EpCAM+CK+CD45-. CTCs enriched from blood of patients with melanoma were defined as MCSP+CD45-. One-hundred-sixteen consecutive blood samples from 70 patients with metastatic carcinomas (n = 48) or metastatic melanoma (n = 22) were analyzed.ResultsCTCs were detected in 47 of 84 blood samples (56%) drawn from carcinoma patients, and in 17 of 32 samples (53%) from melanoma patients. CD45-EpCAM-CK+ was detected in pleural effusion specimens, as well as in peripheral blood samples of patients with NSCLC. EpCAM-CK+ cells have been successfully cultured and passaged longer than six months suggesting their neoplastic origin. This was confirmed by CGH. By defining CTCs in carcinoma patients as CD45-CK+ and/or EpCAM+, the detection rate increased to 73% (61/84).ConclusionEnriching CTCs using CD45 depletion allowed for detection of epithelial cancer cells not displaying the classical phenotype. This potentially leads to a more accurate estimation of the number of CTCs. If detection of CTCs without a classical epithelial phenotype has clinical relevance need to be determined.

[1]  D. Pinkel,et al.  High‐resolution genomic profiling of occult micrometastatic tumor cells , 2003, Genes, chromosomes & cancer.

[2]  M C Miller,et al.  Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Maciej Zborowski,et al.  Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. , 2004, Experimental hematology.

[4]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[6]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[7]  U. Keilholz,et al.  Expression of the stem cell marker nestin in peripheral blood of patients with melanoma , 2010, The British journal of dermatology.

[8]  K. Pantel,et al.  Influence of immunomagnetic enrichment on gene expression of tumor cells , 2005, Journal of Translational Medicine.

[9]  U. Keilholz,et al.  Stem cell marker nestin expression in peripheral blood of patients with melanoma. , 2010 .

[10]  R. Moll,et al.  The human keratins: biology and pathology , 2008, Histochemistry and Cell Biology.

[11]  E. Thiel,et al.  Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  U. Reichelt,et al.  Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. , 2011, The Journal of investigative dermatology.

[13]  H. Ju,et al.  Circulating Tumor Cells in Perioperative Esophageal Cancer Patients: Quantitative Assay System and Potential Clinical Utility , 2007, Clinical Cancer Research.

[14]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[15]  C. Prior,et al.  Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[16]  T. Kroll,et al.  Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[18]  L. Sobin,et al.  Classification of isolated tumor cells , 2003, Cancer.

[19]  E. Thiel,et al.  Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma , 2007, Clinical Cancer Research.

[20]  D. Schadendorf,et al.  Functional CCR9 expression is associated with small intestinal metastasis. , 2004, The Journal of investigative dermatology.

[21]  M. Kitajima,et al.  Clinical Significance of Circulating Tumor Cells in Blood from Patients with Gastrointestinal Cancers , 2008, Annals of Surgical Oncology.

[22]  P. Bunn,et al.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma , 2007, Molecular Cancer Therapeutics.

[23]  M. Wirth,et al.  Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. , 2002, International journal of oncology.

[24]  M. Tan,et al.  The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method , 2008, Breast Cancer Research and Treatment.

[25]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[26]  Philipp Busch,et al.  Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. , 2005, Journal of the National Cancer Institute.

[27]  N. Tsubota,et al.  Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer , 2009, Clinical Cancer Research.

[28]  J. Chalmers,et al.  Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells , 2009, Biotechnology and bioengineering.

[29]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[31]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[33]  B. Naume,et al.  Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern , 2011, Breast Cancer Research and Treatment.

[34]  U. Schumacher,et al.  Epithelial Glycoprotein-2 Expression is Subject to Regulatory Processes in Epithelial–mesenchymal Transitions During Metastases: an Investigation of Human Cancers Transplanted into Severe Combined Immunodeficient Mice , 1998, The Histochemical Journal.

[35]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[36]  Falk Schubert,et al.  Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. , 2005, Journal of immunological methods.

[37]  D. Krag,et al.  Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients , 2008, Breast Cancer Research.

[38]  H. Taubert,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[39]  E. Thiel,et al.  Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2004, Clinical Cancer Research.

[40]  H. Taubert,et al.  Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. , 2004, Gynecologic oncology.

[41]  Heike Pohla,et al.  Isolation of circulating cancer cells from whole blood by immunomagnetic cell enrichment and unenriched immunocytochemistry in vitro. , 2003, The Journal of urology.

[42]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[43]  A. Giuliano,et al.  Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.

[44]  A. Look,et al.  Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. , 2007, Cancer research.